Perspective Therapeutics, Inc.
CATX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.15 | -0.14 | 0.04 | -0.01 |
| FCF Yield | -7.17% | -7.67% | -17.02% | -18.30% |
| EV / EBITDA | -9.21 | -10.30 | -6.56 | -4.03 |
| Quality | ||||
| ROIC | -10.13% | -8.05% | -6.87% | -13.20% |
| Gross Margin | -270.81% | -152.76% | -114.04% | 0.00% |
| Cash Conversion Ratio | 0.63 | -2.14 | 1.19 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -50.83% | -54.88% | -64.87% | -100.00% |
| Free Cash Flow Growth | 1.92% | 28.95% | 36.35% | -56.45% |
| Safety | ||||
| Net Debt / EBITDA | 0.93 | 1.20 | 2.34 | 1.38 |
| Interest Coverage | -428.63 | -202.01 | -170.56 | 616.22 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,426.56 | -795.55 | -1,053.33 | 0.00 |